论文部分内容阅读
目的讨论中晚期肝癌肝动脉变异及其在中晚期肝癌介入导管治疗中的临床意义。方法对５５６例中晚期肝癌进行肝动脉介入灌注化疗（ＴｒａｎｒａｔｈｅｔｅｒａｒｔｅｒｉａｌｉｎｆｕｓｉｏｎＴＡＩ）和／或其与化疗栓塞（ＴｒａｎｓｃａｔｈｅｔｅｒａｒｔｅｒｉａｌｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎＴＡＣＥ）联合治疗，治疗前进行肝动脉造影。结果发现肝动脉变异８５例，占１５３％。我们发现肝动脉无变异者生存期长于有变异者。结论应仔细造影观察有无肝动脉变异，尽可能做到插管高选择性。否则，应另寻其他办法或辅以其他治疗来提高疗效。
Objective To discuss the clinical significance of hepatic arterial variation in advanced hepatocellular carcinoma and its application in the interventional catheterization of advanced hepatocellular carcinoma. Methods Transcatheter arterial linfusion (TACE) and/or transcatheter arterial chemoembolization (TACE) were performed on 556 patients with advanced hepatocellular carcinoma. Hepatic arteriography was performed before treatment. Results found 85 cases of hepatic artery variability, accounting for 15 3%. We found that those who had no mutation in the hepatic artery had a longer survival than those with mutations. Conclusion It is necessary to carefully observe the presence of hepatic artery variation and to make the catheter highly selective. Otherwise, other methods should be found or supplemented with other treatments to improve the efficacy.